Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with CTLA-4 blockade

GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors

LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

Spanish drugmaker Grifols swung to a first-quarter net profit of 21 million euros ($23 million) from a year-ago loss, and said on Tuesday it was on track to meet its 2024 outlook, including cutting debt.

Grifols swings to profit, says debt reduction on track

BARCELONA, Spain , April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").

Grifols 2023 Annual Report on Form 20-F filed with the SEC

BARCELONA, Spain, April 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today officially celebrated the 50th anniversary of its flagship site in Clayton, N.C., whose production of these essential therapeutics during its existence has saved the lives of millions of patients.

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

Spanish drug maker Grifols , battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday.

Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper

Spanish drug maker Grifols plans to meet its debt payments in 2025 with the proceeds of new senior secured notes and the sale of its 20% stake in Shanghai RAAS to Haier Group, it said on Wednesday.

Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake

LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

Spanish drugmaker Grifols on Thursday issued new details of its 2022 and 2023 accounts, including higher leverage ratios than previously reported based on a different calculation of its core earnings and debt, after it was required to do so by market supervisor CNMV.

Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor

BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation (IVDR), the first for an automated nucleic acid test (NAT) specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses.

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS

Shares in Grifols fell more than 9% on Thursday after credit rating agencies Fitch and S&P downgraded their ratings for the beleaguered Spanish drugmaker, citing lower than expected free cash flow generation and refinancing risks.

Shares in Spanish drugmaker Grifols tumble on Fitch, S&P downgrades

Shares in Spanish drugmaker Grifols fell to a 12-year low on Wednesday, following the publication of a new report by Gotham City Research questioning the financial accounts of the Barcelona-based company.

Grifols shares drop to 12-year low after new Gotham City Research report

Shares in Spanish drugmaker Grifols fell nearly 15% in early trading on Wednesday following the publication of a new report by Gotham City Research questioning the Barcelona-based company's "transparency, integrity and ethical conduct".

Grifols shares drop 15% after new Gotham City Research report

Grifols' $1.8 billion sale of a 20% stake in Shanghai RAAS will proceed after a due diligence process concluded "satisfactorily", the Spanish drug maker said on Friday.

Grifols says due diligence done, Shanghai RAAS stake sale to go ahead

Spanish drug maker Grifols' top executive Thomas Glanzmann said on Thursday he will become non-executive chairman in 2025 as part of the beleaguered company's management overhaul. Glanzmann, who is currently both chief executive and executive chairman, had said earlier this month he would leave the CEO job on April 1, but remain executive chairman afterwards.

Grifols CEO Glanzmann to become non-executive chairman in 2025

Spanish pharma group Grifols was silent on the short-selling attack from Gotham City Research in today's annual earnings call. Grifols found itself under scrutiny from US-based Gotham City earlier this month for its ties with a company called Scranton Enterprise, among other accounting irregularities.

Grifols hushed on Gotham City short-sell attack during annual results

Gotham City Research has once again questioned the Spanish pharma group Grifols' ties with a company called Scranton Enterprises. Gotham via its website has posed a series of incendiary questions, following on from its negative analysis last month.

Gotham City Research once again questions Grifols

Short seller Gotham City Research has renewed its campaign against Spanish pharmaceutical company Grifols, after its responses to Gotham's original hit piece failed to cut the mustard. Gotham's short-selling report published in January focused on Grifols' handling of debt and its relationship with Scranton Enterprises, a family-owned entity connected to Grifols.

Gotham City Research renews short-sell attack on Grifols

Short-seller fund Gotham City Research on Tuesday issued a second report on Grifols , maintaining some of its questions over the Spanish pharmaceutical company's accounting practices.

Gotham City issues new report on Grifols, maintains questions over accounting practices

Zoetis

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

GRFS or ZTS: Which Is the Better Value Stock Right Now?

BARCELONA, Spain, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced that Biotest's positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate (FC), BT524, advance this potential treatment for acquired fibrinogen deficiency (AFD), an underserved growth market.

Grifols announces positive topline phase 3 fibrinogen clinical trial results

LOS ANGELES, CA / ACCESSWIRE / February 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

News for Grifols, S.A. Stock (GRFS)